Many patients report fewer side effects, and it is typically less expensive than tirzepatide
In SURMOUNT-1, published in NEJM in 2022, tirzepatide at the 15 mg weekly dose produced a mean placebo-adjusted body weight reduction of 17.8% at 72 weeks in adults with obesity (Jastreboff et al., NEJM, 2022)
By marking a vial research use only or not for human consumption, a seller sidesteps the rules that govern drugs meant for people
Each medicationincluding the exposure and control medicationswas only considered used if an individual had redeemed at least three prescriptions in the period outlined above
The amount of regain varies individually and can be influenced by lifestyle modifications, though some regain typically occurs due to biological factors
Severe or intolerable side effects may be a reason to switch GLP-1 medications